Cyclo Therapeutics(CYTH) - 2023 Q1 - Quarterly Report

Financial Performance - The company reported a net loss of approximately $5,007,085 for the three months ended March 31, 2023, compared to a net loss of approximately $2,772,000 for the same period in 2022, indicating a significant increase in losses [99]. - Total revenues for the three-month period ended March 31, 2023, decreased by 23% to approximately $150,000 compared to approximately $195,000 for the same period in 2022 [100]. - Sales of Trappsol® Cyclo™ for the three-month period ended March 31, 2023, were approximately $53,000, with no sales recorded for the same period in 2022, highlighting the product's orphan drug status [100]. Research and Development - Research and development expenses increased by 213% to approximately $3,398,000 for the three months ended March 31, 2023, from approximately $1,084,000 for the same period in 2022, reflecting increased activity in the Phase III study of Trappsol® Cyclo™ [109]. - The company received IND clearance from the FDA for a Phase II study of Trappsol® Cyclo™ for the treatment of Alzheimer's disease, with patient dosing beginning in Q1 2023 [96]. Financial Position - Cash decreased to approximately $915,176 as of March 31, 2023, compared to approximately $1,543,000 as of December 31, 2022, indicating liquidity challenges [112]. - The company had negative working capital of approximately $506,000 as of March 31, 2023, compared to positive working capital of approximately $678,000 at December 31, 2022 [112]. - As of December 31, 2022, the company had approximately $42,395,000 in net state and federal operating loss carryforwards, including $33,997,000 that will not expire, which can be utilized to offset future taxable net income [115]. - A 100% valuation allowance has been provided on the deferred tax asset due to expected future expenses related to clinical trials and development initiatives [115]. Operational Changes - Personnel expenses decreased by 25% to approximately $907,000 for the three months ended March 31, 2023, from approximately $1,217,000 for the same period in 2022, due to reallocation of personnel time [108]. - The company operates a legacy fine chemical business while transitioning to a biotechnology focus, primarily developing cyclodextrin-based biopharmaceuticals [98]. Capital and Financing - The company expects to continue raising additional capital through the sale of securities to fund ongoing operations and clinical trials, indicating reliance on external financing [113]. Accounting Policies - There were no off-balance sheet arrangements as of March 31, 2023 [116]. - No significant changes to critical accounting policies occurred during the quarter ended March 31, 2023 [118]. - The financial statements are prepared in accordance with U.S. generally accepted accounting principles, requiring judgments, estimates, and assumptions that may affect reported amounts [117].